SC 13G 1 schedule13g.htm

	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

	SCHEDULE 13G
	Under the Securities Exchange Act of 1934
	(Amendment No. __)*

	Altimmune, Inc.
	(Name of Issuer)

	Common Stock
	(Title of Class of Securities)

	02155H200
	(CUSIP Number)

	June 27, 2022
	(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[ ]	Rule 13d-1(b)

[x]	Rule 13d-1(c)

[ ]	Rule 13d-1(d)

___________________________________

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1	Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only) Cormorant Global Healthcare Master Fund, LP
2	Check the Appropriate Box if a Member of a Group (See Instructions)
	(a) [ ]
	(b) [x]
3	SEC Use Only
4	Citizenship or Place of Organization. Cayman Islands
Number of Shares Beneficially Owned by Each Reporting Person With		5 Sole Voting Power 0 shares
		6 Shared Voting Power 2,650,000 shares (3,000,000 shares as of the date of filing) Refer to Item 4 below.
		7 Sole Dispositive Power 0 shares
		8 Shared Dispositive Power 2,650,000 shares (3,000,000 shares as of the date of filing) Refer to Item 4 below.
9	Aggregate Amount Beneficially Owned by Each Reporting Person 2,650,000 shares (3,000,000 shares as of the date of filing) Refer to Item 4 below.
10	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] N/A
11	Percent of Class Represented by Amount in Row (9)* 6.13% (6.94% as of the date of filing) Refer to Item 4 below.
12	Type of Reporting Person (See Instructions) PN (Partnership)

1	Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only) Cormorant Global Healthcare GP, LLC
2	Check the Appropriate Box if a Member of a Group (See Instructions)
	(a) [ ]
	(b) [x]
3	SEC Use Only
4	Citizenship or Place of Organization. Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5 Sole Voting Power 0 shares
		6 Shared Voting Power 2,650,000 shares (3,000,000 shares as of the date of filing) Refer to Item 4 below.
		7 Sole Dispositive Power 0 shares
		8 Shared Dispositive Power 2,650,000 shares (3,000,000 shares as of the date of filing) Refer to Item 4 below.
9	Aggregate Amount Beneficially Owned by Each Reporting Person 2,650,000 shares (3,000,000 shares as of the date of filing) Refer to Item 4 below.
10	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] N/A
11	Percent of Class Represented by Amount in Row (9)* 6.13% (6.94% as of the date of filing) Refer to Item 4 below.
12	Type of Reporting Person (See Instructions) OO (Limited Liability Company)

1	Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only) Cormorant Asset Management, LP
2	Check the Appropriate Box if a Member of a Group (See Instructions)
	(a) [ ]
	(b) [x]
3	SEC Use Only
4	Citizenship or Place of Organization. Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5 Sole Voting Power 0 shares
		6 Shared Voting Power 2,650,000 shares (3,000,000 shares as of the date of filing) Refer to Item 4 below.
		7 Sole Dispositive Power 0 shares
		8 Shared Dispositive Power 2,650,000 shares (3,000,000 shares as of the date of filing) Refer to Item 4 below.
9	Aggregate Amount Beneficially Owned by Each Reporting Person 2,650,000 shares (3,000,000 shares as of the date of filing) Refer to Item 4 below.
10	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] N/A
11	Percent of Class Represented by Amount in Row (9)* 6.13% (6.94% as of the date of filing) Refer to Item 4 below.
12	Type of Reporting Person (See Instructions) PN (Partnership)

1	Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only) Bihua Chen
2	Check the Appropriate Box if a Member of a Group (See Instructions)
	(a) [ ]
	(b) [x]
3	SEC Use Only
4	Citizenship or Place of Organization. United States
Number of Shares Beneficially Owned by Each Reporting Person With		5 Sole Voting Power 0 shares
		6 Shared Voting Power 2,650,000 shares (3,000,000 shares as of the date of filing) Refer to Item 4 below.
		7 Sole Dispositive Power 0 shares
		8 Shared Dispositive Power 2,650,000 shares (3,000,000 shares as of the date of filing) Refer to Item 4 below.
9	Aggregate Amount Beneficially Owned by Each Reporting Person 2,650,000 shares (3,000,000 shares as of the date of filing) Refer to Item 4 below.
10	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] N/A
11	Percent of Class Represented by Amount in Row (9)* 6.13% (6.94% as of the date of filing) Refer to Item 4 below.
12	Type of Reporting Person (See Instructions) IN (Individual)

Item 1.

	(a)	Name of Issuer

		Altimmune, Inc.
	(b)	Address of Issuer’s Principal Executive Offices
		910 Clopper Road, Suite 201S, Gaithersburg, MD 20878

Item 2.

	(a)	Name of Person Filing

		Cormorant Global Healthcare Master Fund, LP Cormorant Global Healthcare GP, LLC Cormorant Asset Management, LP Bihua Chen
	(b)	Address of Principal Business Office or, if none, Residence

		200 Clarendon Street, 52nd Floor Boston, MA 02116
	(c)	Citizenship
		Cormorant Global Healthcare Master Fund, LP - Cayman Islands Cormorant Global Healthcare GP, LLC - Delaware Cormorant Asset Management, LP - Delaware Bihua Chen - United States
	(d)	Title of Class of Securities

		Common Stock
	(e)	CUSIP Number
		02155H200

Item 3.

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)	[ ]	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
(b)	[ ]	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c)	[ ]	Insurance Company as defined in Section 3(a)(19) of the Act
(d)	[ ]	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
(e)	[ ]	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
(f)	[ ]	An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
(g)	[ ]	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	[ ]	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	[ ]	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	[ ]	A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
(k)	[ ]	Group, in accordance with §240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership***

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

	(a)	Amount Beneficially Owned***
		Cormorant Global Healthcare Master Fund, LP – 2,650,000 shares (3,000,000 shares as of the date of filing) Cormorant Global Healthcare GP, LLC – 2,650,000 shares (3,000,000 shares as of the date of filing) Cormorant Asset Management, LP – 2,650,000 shares (3,000,000 shares as of the date of filing) Bihua Chen – 2,650,000 shares (3,000,000 shares as of the date of filing)

	(b)	Percent of Class
		Cormorant Global Healthcare Master Fund, LP – 6.13% (6.94% as of the date of filing) Cormorant Global Healthcare GP, LLC – 6.13% (6.94% as of the date of filing) Cormorant Asset Management, LP – 6.13% (6.94% as of the date of filing) Bihua Chen – 6.13% (6.94% as of the date of filing)

	(c)	Number of shares as to which such person has:
		(i)	sole power to vote or to direct the vote

			Cormorant Global Healthcare Master Fund, LP - 0 shares Cormorant Global Healthcare GP, LLC - 0 shares Cormorant Asset Management, LP - 0 shares Bihua Chen - 0 shares
		(ii)	shared power to vote or to direct the vote
			Cormorant Global Healthcare Master Fund, LP – 2,650,000 shares (3,000,000 shares as of the date of filing) Cormorant Global Healthcare GP, LLC – 2,650,000 shares (3,000,000 shares as of the date of filing) Cormorant Asset Management, LP – 2,650,000 shares (3,000,000 shares as of the date of filing) Bihua Chen – 2,650,000 shares (3,000,000 shares as of the date of filing)

		(iii)	sole power to dispose or to direct the disposition of
			Cormorant Global Healthcare Master Fund, LP - 0 shares Cormorant Global Healthcare GP, LLC - 0 shares Cormorant Asset Management, LP - 0 shares Bihua Chen - 0 shares
		(iv)	shared power to dispose or to direct the disposition of
			Cormorant Global Healthcare Master Fund, LP – 2,650,000 shares (3,000,000 shares as of the date of filing) Cormorant Global Healthcare GP, LLC – 2,650,000 shares (3,000,000 shares as of the date of filing) Cormorant Asset Management, LP – 2,650,000 shares (3,000,000 shares as of the date of filing) Bihua Chen – 2,650,000 shares (3,000,000 shares as of the date of filing)

*** Shares reported herein for Cormorant Asset Management, LP represent shares which are beneficially owned by Cormorant Global Healthcare Master Fund, LP (the “Master Fund”), as reported herein. Cormorant Global Healthcare GP, LLC serves as the general partner of the Master Fund. Cormorant Asset Management, LP serves as the investment manager to the Master Fund. Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC and the general partner of Cormorant Asset Management, LP. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein.

The percentages reported herein with respect to the Reporting Persons’ holdings are calculated based upon a statement in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022, as filed with the Securities and Exchange Commission on May 12, 2022, that there were 43,219,358 shares of Common Stock of the Issuer outstanding as of May 10, 2022.

Item 5.

Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

Not applicable.

Item 8.

Identification and Classification of Members of the Group

Not applicable.

Item 9.

Notice of Dissolution of Group

Not applicable.

Item 10.

Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Exhibits

Exhibit

99.1	Joint Filing Agreement by and among the Reporting Persons.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

July 7, 2022

	CORMORANT GLOBAL HEALTHCARE
	MASTER FUND, LP
	By: Cormorant Global Healthcare GP, LLC
	its General Partner

	By: /s/ Bihua Chen
	Bihua Chen, Managing Member

	CORMORANT GLOBAL HEALTHCARE GP,
	LLC

	By: /s/ Bihua Chen
	Bihua Chen, Managing Member

	CORMORANT ASSET MANAGEMENT, LP
	By: Cormorant Asset Management GP, LLC
	its General Partner

	By: /s/ Bihua Chen
	Bihua Chen, Managing Member

	/s/ Bihua Chen
	Bihua Chen

SEC Form SC 13G filed by Altimmune Inc.